Investor Presentation: First Nine Months of 2020

37 Investor presentation First nine months of 2020 B-cell function Diabetes is a chronic disease requiring treatment intensification over time Diet and exercise Time 100% OAD GLP-1 Distribution of patients and value across treatment classes 5% 18% 80% 44% 13% 60% 20% 18% Insulin 40% 4% 8% 20% 43% 26% 0% Patients Value Insulin GLP-1 SGLT2i DPP-IV Traditional OADs Note: Patient distribution across treatment classes is indicative and based on data for the USA, Germany and France. Other OADS covers: metformin, sulfonylurea, thiazolidinediones. Source: IQVIA PharMetrix claims data, IQVIA disease analyser, IQVIA MIDAS; value figures based on IQVIA MAT, Aug 2020 OAD: Oral anti-diabetic Novo Nordisk®

View entire presentation